Role of corticotropin-releasing factor in drug addiction: Potential for pharmacological intervention

CNS Drugs

Volumn 25, Issue 4, 2011, Pages 271-287

  Logrip, Marian L ^a   Koob, George F ^a   Zorrilla, Eric P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Corticotropin releasing factor receptor 1 antagonists, therapeutic use; Corticotropin releasing factor receptor 2 antagonists, therapeutic use; Corticotropin releasing factor receptor antagonists, therapeutic use; Drug abuse; Hypothalamic pituitary adrenal axis; Stress

Indexed keywords

3 (4 CHLORO 2 MORPHOLIN 4 YL THIAZOL 5 YL) 8 (1 ETHYLPROPYL) 2,6 DIMETHYL IMIDAZO[1,2 B]PYRIDAZINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ALCOHOL; ALPHA HELICAL CORTICOTROPIN RELEASING FACTOR; AMPHETAMINE; ANTALARMIN; COCAINE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CP 154 526; D PHE CRF (12-41); DRONABINOL; GLUCOCORTICOID RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LWH 63; MESSENGER RNA; MJL 1 109 2; N,N BIS(2 METHOXYETHYL) 3 (4 METHOXY 2 METHYLPHENYL) 2,5 DIMETHYL PYRAZOLO[1,5 A] PYRIMIDIN 7 AMINE; NICOTINE; OPIATE DERIVATIVE; UNCLASSIFIED DRUG;

ALPHA HELIX; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BEHAVIOR DISORDER; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; GENE DELETION; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCOMOTION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RELAPSE; SENSITIZATION; STRESS;

ANIMALS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; MOTIVATION; NEUROPEPTIDES; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 79952956137     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11587790-000000000-00000     Document Type: Article

References (175)

1. Koob GF. A role for brain stress systems in addiction. Neuron 2008 Jul 10; 59 (1): 11-34. (Pubitemid 351905857)
2. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 2008 Oct; 1141: 105-30.
3. Goeders NE. The impact of stress on addiction. Eur Neuropsychopharmacol 2003 Dec; 13 (6): 435-41. (Pubitemid 37433963)
4. Weiss F, Ciccocioppo R, Parsons LH, et al. Compulsive drug-seeking behavior and relapse: neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 2001 Jun; 937: 1-26. (Pubitemid 32613877)
5. De Luca V, Tharmalingam S, Kennedy JL. Association study between the corticotropin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur Psychiatry 2007 Jul; 22 (5): 282-7. (Pubitemid 47088197)
6. Enoch MA, Shen PH, Ducci F, et al. Common genetic origins for EEG, alcoholism and anxiety: the role of CRH-BP. PLoS One 2008; 3 (10): e3620.
7. Clarke TK, Schumann G. Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol Biochem Behav 2009 Sep; 93 (3): 230-6.
8. Blomeyer D, Treutlein J, Esser G, et al. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry 2008 Jan 15; 63 (2): 146-51. (Pubitemid 350299326)
9. Treutlein J, Kissling C, Frank J, et al. Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 2006 Jun; 11 (6): 594-602.
10. Spiess J, Rivier J, Rivier C, et al. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci USA 1981 Oct; 78 (10): 6517-21. (Pubitemid 12179744)
11. Chang CP, Pearse 2nd RV, O'Connell S, et al. Identification of a seven transmembrane helix receptor for corticotropin- releasing factor and sauvagine in mammalian brain. Neuron 1993 Dec; 11 (6): 1187-95.
12. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin- releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995 Jan 31; 92 (3): 836-40.
13. Grammatopoulos DK, Randeva HS, Levine MA, et al. Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. J Neurochem 2001 Jan; 76 (2): 509-19. (Pubitemid 32097028)
14. Blank T, Nijholt I, Grammatopoulos DK, et al. Corticotropin- releasing factor receptors couple to multiple Gproteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning. J Neurosci 2003 Jan 15; 23 (2): 700-7. (Pubitemid 36139569)
15. Linton EA, Behan DP, Saphier PW, et al. Corticotropinreleasing hormone (CRH)-binding protein: reduction in the adrenocorticotropin-releasing activity of placental but not hypothalamic CRH. J Clin Endocrinol Metab 1990 Jun; 70 (6): 1574-80.
16. Guillemin R, Dear WE, Nichols Jr B, et al. ACTH releasing activity in vivo of a CRF preparation and lysine vasopressin. Proc Soc Exp Biol Med 1959 May; 101 (1): 107-11.
17. Hiroshige T, Ogura C, Itoh S. ACTH release by purified hypothalamicCRF preparation as assayed by intrapituitary microinjection. Endocrinol Jpn 1968 Sep; 15 (3): 379-82.
18. McEwen BS. Influences of adrenocortical hormones on pituitary and brain function. Monogr Endocrinol 1979; 12: 467-92.
19. Kretz O, Reichardt HM, Schutz G, et al. Corticotropinreleasing hormone expression is the major target for glucocorticoid feedback-control at the hypothalamic level. Brain Res 1999 Feb 13; 818 (2): 488-91. (Pubitemid 29229963)
20. Heinrichs SC, Menzaghi F,Merlo Pich E, et al. The role of CRF in behavioral aspects of stress. Ann N Y Acad Sci 1995 Dec 29; 771: 92-104. (Pubitemid 26077399)
21. Pilcher WH, Joseph SA. Co-localization of CRF-ir perikarya and ACTH-ir fibers in rat brain. Brain Res 1984 May 7; 299 (1): 91-102. (Pubitemid 14143642)
22. Melia KR, Sananes CB, Davis M. Lesions of the central nucleus of the amygdala block the excitatory effects of septal ablation on the acoustic startle reflex. Physiol Behav 1992 Jan; 51 (1): 175-80.
23. Day HE, Nebel S, Sasse S, et al. Inhibition of the central extended amygdala by loud noise and restraint stress. Eur J Neurosci 2005 Jan; 21 (2): 441-54. (Pubitemid 40204247)
24. Hammack SE, Richey KJ, Watkins LR, et al. Chemical lesion of the bed nucleus of the stria terminalis blocks the behavioral consequences of uncontrollable stress. Behav Neurosci 2004 Apr; 118 (2): 443-8. (Pubitemid 38445623)
25. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999 Nov 1; 46 (9): 1167-80. (Pubitemid 30114435)
26. Potter E, Behan DP, Linton EA, et al. The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci USA 1992 May 1; 89 (9): 4192-6.
27. De Souza EB, Battaglia G. Corticotropin-releasing hormone (CRH) receptors in brain. Adv ExpMed Biol 1988; 245: 123-36.
28. Swinny JD, Kalicharan D, Blaauw EH, et al. Corticotropin- releasing factor receptor types 1 and 2 are differentially expressed in pre- and post-synaptic elements in the post-natal developing rat cerebellum. Eur J Neurosci 2003 Aug; 18 (3): 549-62. (Pubitemid 37041104)
29. Schierloh A, Deussing J, Wurst W, et al. Corticotropinreleasing factor (CRF) receptor type 1-dependent modulation of synaptic plasticity. Neurosci Lett 2007 Apr 6; 416 (1): 82-6. (Pubitemid 46428019)
30. Fu Y, Neugebauer V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in painrelated synaptic facilitation and behavior. JNeurosci 2008 Apr 9; 28 (15): 3861-76.
31. Miyata M, Okada D, Hashimoto K, et al. Corticotropinreleasing factor plays a permissive role in cerebellar longterm depression. Neuron 1999 Apr; 22 (4): 763-75. (Pubitemid 29203499)
32. Rainnie DG, Bergeron R, Sajdyk TJ, et al. Corticotrophin releasing factor-induced synaptic plasticity in the amyg- dala translates stress into emotional disorders. J Neurosci 2004 Apr 7; 24 (14): 3471-9. (Pubitemid 38481103)
33. Schmolesky MT, De Ruiter MM, De Zeeuw CI, et al. The neuropeptide corticotropin-releasing factor regulates excitatory transmission and plasticity at the climbing fibre- Purkinje cell synapse. Eur J Neurosci 2007 Mar; 25 (5): 1460-6. (Pubitemid 46568774)
34. Gallagher JP, Orozco-Cabal LF, Liu J, et al. Synaptic physiology of central CRH system. Eur J Pharmacol 2008 Apr 7; 583 (2-3): 215-25.
35. Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000 Dec 11; 428 (2): 191-212.
36. Potter E, Sutton S, Donaldson C, et al. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 1994 Sep 13; 91 (19): 8777-81.
37. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995 Oct; 15 (10): 6340-50.
38. Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998 Jun; 19 (2): 162-6. (Pubitemid 28248798)
39. Muller MB, Zimmermann S, Sillaber I, et al. Limbic corticotropin- releasing hormone receptor 1 mediates anxietyrelated behavior and hormonal adaptation to stress. Nat Neurosci 2003 Oct; 6 (10): 1100-7. (Pubitemid 37186203)
40. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety- like behaviour and are hypersensitive to stress. Nat Genet 2000 Apr; 24 (4): 410-4. (Pubitemid 30187443)
41. Kishimoto T, Radulovic J, Radulovic M, et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000 Apr; 24 (4): 415-9. (Pubitemid 30187444)
42. Coste SC, Kesterson RA, Heldwein KA, et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin- releasing hormone receptor-.Nat Genet 2000 Apr; 24 (4): 403-9. (Pubitemid 30187442)
43. Coste SC, Heard AD, Phillips TJ, et al. Corticotropin-releasing factor receptor type 2-deficient mice display impaired coping behaviors during stress. Genes Brain Behav 2006 Mar; 5 (2): 131-8. (Pubitemid 43344965)
44. Buckingham JC. Secretion of corticotrophin and its hypothalamic releasing factor in response to morphine and opioid peptides. Neuroendocrinology 1982; 35 (2): 111-6. (Pubitemid 12081717)
45. Swerdlow NR, Koob GF, CadorM, et al. Pituitary-adrenal axis responses to acute amphetamine in the rat. Pharmacol Biochem Behav 1993 Jul; 45 (3): 629-37.
46. Calogero AE, Gallucci WT, Kling MA, et al. Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res 1989 Dec 25; 505 (1): 7-11. (Pubitemid 20011104)
47. Buckingham JC, Hodges JR. Hypothalamic receptors influencing the secretion of corticotrophin releasing hormone in the rat. J Physiol 1979 May; 290 (2): 421-31. (Pubitemid 9194162)
48. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994 Feb; 59 (2): 110-2. (Pubitemid 24032705)
49. Rivier C, Bruhn T, Vale W. Effect of ethanol on the hypothalamic- pituitary-adrenal axis in the rat: role of corticotropin-releasing factor (CRF). J Pharmacol Exp Ther 1984 Apr; 229 (1): 127-31. (Pubitemid 14082921)
50. Rivier CL, Grigoriadis DE, Rivier JE. Role of corticotropin- releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology 2003 Jun; 144 (6): 2396-403. (Pubitemid 36629890)
51. Sarnyai Z, Biro E, Penke B, et al. The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. Brain Res 1992 Aug 28; 589 (1): 154-6.
52. Cole BJ, Cador M, Stinus L, et al. Critical role of the hypothalamic pituitary adrenal axis in amphetamineinduced sensitization of behavior. Life Sci 1990; 47 (19): 1715-20. (Pubitemid 20374724)
53. Fee JR, Sparta DR, Picker MJ, et al. Corticotropin releasing factor-1 receptor antagonist, CP-154,526, blocks the expression of ethanol-induced behavioral sensitization in DBA/2J mice. Neuroscience 2007 Nov 30; 150 (1): 14-21. (Pubitemid 350198692)
54. Przegalinski E, Filip M, Frankowska M, et al. Effects of CP 154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats. Neuropeptides 2005 Oct; 39 (5): 525-33. (Pubitemid 41443528)
55. Pastor R, McKinnon CS, Scibelli AC, et al. Corticotropinreleasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: a urocortin1-independent mechanism. Proc Natl Acad Sci USA 2008 Jul 1; 105 (26): 9070-5.
56. Goeders NE, Guerin GF. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res 1996 May 25; 722 (1-2): 145-52. (Pubitemid 26199364)
57. Koob GF. The role of CRF and CRF-related peptides in the dark side of addiction. BrainRes 2010 Feb 16; 1314: 3-14.
58. Zhou Y, Spangler R, LaForge KS, et al. Corticotropinreleasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during 'binge'-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 1996 Oct; 279 (1): 351-8.
59. Maj M, Turchan J, Smialowska M, et al. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003 Apr; 37 (2): 105-10. (Pubitemid 37421493)
60. Zorrilla EP, Valdez GR, Weiss F. Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 2001 Dec; 158 (4): 374-81. (Pubitemid 33141313)
61. Zhou Y, Spangler R, Ho A, et al. Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res Mol Brain Res 2003 May 26; 114 (1): 73-9. (Pubitemid 36627998)
62. Caberlotto L, Rimondini R, Hansson A, et al. Corticotropin- releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? Neuropsychopharmacology 2004 Jan; 29 (1): 15-22. (Pubitemid 38068009)
63. Sommer WH, Rimondini R, Hansson AC, et al. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 2008 Jan 15; 63 (2): 139-45. (Pubitemid 350299311)
64. George O, Ghozland S, Azar MR, et al. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci USA 2007 Oct 23; 104 (43): 17198-203. (Pubitemid 350211014)
65. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 2007 Aug; 164 (8): 1149-59. (Pubitemid 47292402)
66. Richter RM, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 1999 Jun 15; 32 (4): 254-61. (Pubitemid 29222639)
67. Olive MF, Koenig HN, Nannini MA, et al. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 2002 May; 72 (1-2): 213-20. (Pubitemid 34251330)
68. Merlo Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995 Aug; 15 (8): 5439-47.
69. Rodriguez de Fonseca F, Carrera MR, Navarro M, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997 Jun 27; 276 (5321): 2050-4. (Pubitemid 27443612)
70. Sarnyai Z, Biro E, Gardi J, et al. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 1995 Mar 27; 675 (1-2): 89-97.
71. Funk CK, O'Dell LE, Crawford EF, et al. Corticotropinreleasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. JNeurosci 2006 Nov 1; 26 (44): 11324-32. (Pubitemid 44772162)
72. Iredale PA, Alvaro JD, Lee Y, et al. Role of corticotropinreleasing factor receptor-1 in opiate withdrawal. J Neurochem 2000 Jan; 74 (1): 199-208. (Pubitemid 30012770)
73. Chu K, Koob GF, Cole M, et al. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 2007 Apr; 86 (4): 813-21. (Pubitemid 46839132)
74. Contarino A, Papaleo F. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 2005 Dec 20; 102 (51): 18649-54. (Pubitemid 43011280)
75. Sharpe AL, Coste SC, Burkhart-Kasch S, et al. Mice deficient in corticotropin-releasing factor receptor type 2 exhibit normal ethanol-associated behaviors. Alcohol Clin Exp Res 2005 Sep; 29 (9): 1601-9. (Pubitemid 41395609)
76. Hansson AC, Cippitelli A, Sommer WH, et al. Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 2006 Oct 10; 103 (41): 15236-41. (Pubitemid 44583194)
77. Papaleo F, Ghozland S, Ingallinesi M, et al. Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology 2008 Nov; 33 (12): 2878-87.
78. Papaleo F, Kitchener P, Contarino A. Disruption of the CRF/CRF1 receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 2007 Feb 15; 53 (4): 577-89. (Pubitemid 46216753)
79. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000 Jul-Aug; 44 (1): 235-49. (Pubitemid 32239479)
80. Zhao H. Lead optimization in the nondrug-like space. Drug Discov Today 2011 Feb; 16 (3-4): 158-63.
81. Curtis AL, Grigoriadis DE, Page ME, et al. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. J Pharmacol Exp Ther 1994 Jan; 268 (1): 359-65. (Pubitemid 24039109)
82. Webster EL, Lewis DB, Torpy DJ, et al. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin- releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996 Dec; 137 (12): 5747-50. (Pubitemid 26423152)
83. Keller C, Bruelisauer A, Lemaire M, et al. Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab Dispos 2002 Feb; 30 (2): 173-6. (Pubitemid 34106536)
84. Lundkvist J, Chai Z, Teheranian R, et al. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 1996 Aug 8; 309 (2): 195-200. (Pubitemid 26268497)
85. Chen C, Wilcoxen KM, Huang CQ, et al. Design of 2,5- dimethyl-3-(6- dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[ 1,5-a]pyrimidine (NBI 30775/R121919) and structure: activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J Med Chem 2004 Sep 9; 47 (19): 4787-98. (Pubitemid 39195568)
86. Chen C, Dagnino Jr R, De Souza EB, et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem 1996 Oct 25; 39 (22): 4358-60. (Pubitemid 26359391)
87. Jagoda E, Contoreggi C, Lee MJ, et al. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. J Med Chem 2003 Aug 14; 46 (17): 3559-62. (Pubitemid 36988642)
88. McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 1999 May; 5 (5): 289-315. (Pubitemid 29238994)
89. Okuyama S, Chaki S, Kawashima N, et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 1999 May; 289 (2): 926-35. (Pubitemid 29191251)
90. Zorrilla EP, Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004 Jul; 13 (7): 799-828. (Pubitemid 39028932)
91. Gehlert DR, Cippitelli A, Thorsell A, et al. 3-(4-Chloro-2- morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethylimidazo[ 1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin- releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 2007 Mar 7; 27 (10): 2718-26. (Pubitemid 46393604)
92. Richardson HN, Zhao Y, Fekete EM, et al. MPZP: a novel smallmolecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav 2008 Feb; 88 (4): 497-510. (Pubitemid 350266794)
93. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010 May; 15 (9-10): 371-83.
94. Specio SE, Wee S, O'Dell LE, et al. CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berl) 2008 Feb; 196 (3): 473-82. (Pubitemid 351191180)
95. Goeders NE, Guerin GF. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 2000 Nov; 23 (5): 577-86.
96. Mello NK, Negus SS, Rice KC, et al. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol Biochem Behav 2006 Dec; 85 (4): 744-51. (Pubitemid 46157139)
97. Basso AM, SpinaM, Rivier J, et al. Corticotropin-releasing factor antagonist attenuates the 'anxiogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) 1999 Jul; 145 (1): 21-30. (Pubitemid 29339759)
98. Erb S, Shaham Y, Stewart J. The role of corticotropinreleasing factor and corticosterone in stress- and cocaineinduced relapse to cocaine seeking in rats. J Neurosci 1998 Jul 15; 18 (14): 5529-36. (Pubitemid 28311967)
99. Shaham Y, Erb S, Leung S, et al. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998 May; 137 (2): 184-90. (Pubitemid 28227336)
100. Goeders NE, Clampitt DM. Potential role for the hypothalamo- pituitary-adrenal axis in the conditioned reinforcer- induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology (Berl) 2002 May; 161 (3): 222-32. (Pubitemid 34591660)
101. Skelton KH, Oren D, Gutman DA, et al. The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacol 2007 Sep 24; 571 (1): 17-24. (Pubitemid 47284048)
102. Greenwell TN, Funk CK, Cottone P, et al. Corticotropinreleasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol 2009 Apr; 14 (2): 130-43.
103. Negus SS, Rice KC. Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology 2009 Mar; 34 (4): 899-911.
104. Heinrichs SC, Menzaghi F, Schulteis G, et al. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 1995 Jan; 6 (1): 74-80.
105. Stinus L, Cador M, Zorrilla EP, et al. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal- induced conditioned place aversion in rats. Neuropsychopharmacology 2005 Jan; 30 (1): 90-8. (Pubitemid 40024403)
106. Shaham Y, Funk D, Erb S, et al. Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 1997 Apr 1; 17 (7): 2605-14. (Pubitemid 27137426)
107. Wang J, Fang Q, Liu Z, et al. Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats. Psychopharmacology (Berl) 2006 Mar; 185 (1): 19-28. (Pubitemid 43289609)
108. Rivier C, Rivier J, Lee S. Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat. Brain Res 1996 May 20; 721 (1-2): 83-90.
109. Funk CK, Zorrilla EP, Lee MJ, et al. Corticotropinreleasing factor 1 antagonists selectively reduce ethanol selfadministration in ethanol-dependent rats. Biol Psychiatry 2007 Jan 1; 61 (1): 78-86. (Pubitemid 44855743)
110. Marinelli PW, Funk D, Juzytsch W, et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 2007 Dec; 195 (3): 345-55. (Pubitemid 350160269)
111. Sparta DR, Sparrow AM, Lowery EG, et al. Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol Clin Exp Res 2008 Feb; 32 (2): 259-65.
112. Lowery EG, Sparrow AM, Breese GR, et al. The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice. Alcohol Clin Exp Res 2008 Feb; 32 (2): 240-8.
113. Lowery EG, Spanos M, Navarro M, et al. CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis. Neuropsychopharmacology 2010 May; 35 (6): 1241-52.
114. Sabino V, Cottone P, Koob GF, et al. Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology (Berl) 2006 Dec; 189 (2): 175-86. (Pubitemid 44691540)
115. Gilpin NW, Richardson HN, Koob GF. Effects of CRF1- receptor and opioid-receptor antagonists on dependenceinduced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 2008 Sep; 32 (9): 1535-42.
116. Valdez GR, Roberts AJ, Chan K, et al. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 2002 Oct; 26 (10): 1494-501. (Pubitemid 35192310)
117. Baldwin HA, Rassnick S, Rivier J, et al. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 1991; 103 (2): 227-32.
118. Wills TA, Knapp DJ, Overstreet DH, et al. Sensitization, duration, and pharmacological blockade of anxiety-like behavior following repeated ethanol withdrawal in adolescent and adult rats. Alcohol Clin Exp Res 2009 Mar; 33 (3): 455-63.
119. Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin- releasing factor and opioid mechanisms. J Neurosci 2002 Sep 15; 22 (18): 7856-61. (Pubitemid 35379090)
120. Le AD, Harding S, Juzytsch W, et al. The role of corticotrophin- releasing factor in stress-induced relapse to alcohol- seeking behavior in rats. Psychopharmacology (Berl) 2000 Jun; 150 (3): 317-24. (Pubitemid 30447852)
121. Sparta DR, Ferraro 3rd FM, Fee JR, et al. The alcohol deprivation effect in C57BL/6J mice is observed using operant self-administration procedures and is modulated by CRF-1 receptor signaling. Alcohol Clin Exp Res 2009 Jan; 33 (1): 31-42.
122. Okada S, Shimizu T, Yokotani K. Extrahypothalamic corticotropin-releasing hormone mediates (-)-nicotine-induced elevation of plasma corticosterone in rats. Eur J Pharmacol 2003 Jul 25; 473 (2-3): 217-23. (Pubitemid 36929887)
123. Tucci S, Cheeta S, Seth P, et al. Corticotropin releasing factor antagonist, alpha-helical CRF(9-41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology (Berl) 2003 May; 167 (3): 251-6. (Pubitemid 36712971)
124. Marcinkiewcz CA, Prado MM, Isaac SK, et al. Corticotropin- releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 2009 Jun; 34 (7): 1743-52.
125. Zislis G, Desai TV, Prado M, et al. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2- adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007 Dec; 53 (8): 958-66. (Pubitemid 350137393)
126. Bruijnzeel AW, Prado M, Isaac S. Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawalinduced deficit in brain reward function and stressinduced relapse. Biol Psychiatry 2009 Jul 15; 66 (2): 110-7.
127. Rodriguez de Fonseca F, Rubio P, Menzaghi F, et al. Corticotropin- releasing factor (CRF) antagonist [DPhe12, Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996 Jan; 276 (1): 56-64.
128. Cottone P, Sabino V, Roberto M, et al. CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci USA 2009 Nov 24; 106 (47): 20016-20.
129. Ghitza UE, Gray SM, Epstein DH, et al. The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology 2006 Oct; 31 (10): 2188-96. (Pubitemid 44413196)
130. Rivier J, Rivier C, Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 1984May 25; 224 (4651): 889-91. (Pubitemid 14102465)
131. Menzaghi F, Howard RL, Heinrichs SC, et al. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994 May; 269 (2): 564-72. (Pubitemid 24157322)
132. Erb S, Stewart J. A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin- releasing factor on stress-induced reinstatement of cocaine seeking. J Neurosci 1999 Oct 15; 19 (20): RC35.
133. Wang B, Shaham Y, Zitzman D, et al. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking. J Neurosci 2005 Jun 1; 25 (22): 5389-96. (Pubitemid 40770919)
134. Shalev U, Finnie PS, Quinn T, et al. A role for corticotropin- releasing factor, but not corticosterone, in acute food-deprivation-induced reinstatement of heroin seeking in rats. Psychopharmacology (Berl) 2006 Aug; 187 (3): 376-84. (Pubitemid 44079929)
135. Finn DA, Snelling C, Fretwell AM, et al. Increased drinking during withdrawal from intermittent ethanol exposure is blocked by the CRF receptor antagonist D-Phe- CRF(12-41). Alcohol Clin Exp Res 2007 Jun; 31 (6): 939-49. (Pubitemid 46776166)
136. Rassnick S, Heinrichs SC, Britton KT, et al. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 1993 Mar 5; 605 (1): 25-32. (Pubitemid 23083057)
137. Bruijnzeel AW, Zislis G, Wilson C, et al. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 2007 Apr; 32 (4): 955-63. (Pubitemid 46426186)
138. Bruijnzeel AW, Small E, Pasek TM, et al. Corticotropinreleasing factor mediates the dysphoria-like state associated with alcohol withdrawal in rats. Behav Brain Res 2010 Jul 11; 210 (2): 288-91.
139. Schulz DW, Mansbach RS, Sprouse J, et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996 Sep 17; 93 (19): 10477-82. (Pubitemid 26314648)
140. Zorrilla EP, Valdez GR, Nozulak J, et al. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 2002 Oct 18; 952 (2): 188-99.
141. Moffett MC, Goeders NE. CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine- induced reinstatement of extinguished methamphetamine- seeking behavior in rats. Psychopharmacology (Berl) 2007 Feb; 190 (2): 171-80. (Pubitemid 46011177)
142. Lu L, Ceng X, Huang M. Corticotropin-releasing factor receptor type I mediates stress-induced relapse to opiate dependence in rats. Neuroreport 2000 Aug 3; 11 (11): 2373-8. (Pubitemid 30622274)
143. Lu L, Liu D, Ceng X, et al. Differential roles of corticotropin- releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 2000 Dec; 12 (12): 4398-404. (Pubitemid 32037848)
144. Lu L, Liu D, Ceng X. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaineconditioned place preference in rats. Eur J Pharmacol 2001 Mar; 415 (2-3): 203-8. (Pubitemid 32239465)
145. Breese GR, Overstreet DH, Knapp DJ, et al. Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and benzodiazepinereceptor antagonists and a 5-HT1a-receptor agonist. Neuropsychopharmacology 2005 Sep; 30 (9): 1662-9. (Pubitemid 43086023)
146. Wills TA, Knapp DJ, Overstreet DH, et al. Interactions of stress and CRF in ethanol-withdrawal induced anxiety in adolescent and adult rats. Alcohol Clin Exp Res 2010 Sep 1; 34 (9): 1603-12.
147. Arborelius L, Skelton KH, Thrivikraman KV, et al. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 2000 Aug; 294 (2): 588-97. (Pubitemid 30490833)
148. Overstreet DH, Knapp DJ, Breese GR. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav 2004 Feb; 77 (2): 405-13. (Pubitemid 38125175)
149. Knapp DJ, Overstreet DH, Moy SS, et al. SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol 2004 Feb; 32 (2): 101-11. (Pubitemid 38668688)
150. Heinrichs SC, De Souza EB, Schulteis G, et al. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002 Aug; 27 (2): 194-202. (Pubitemid 34686971)
151. KeckME,Welt T,WiggerA, et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001 Jan; 13 (2): 373-80. (Pubitemid 32142482)
152. Oshima A, Flachskamm C, Reul JM, et al. Altered serotonergic neurotransmission but normal hypothalamic-pituitary- adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775. Neuropsychopharmacology 2003 Dec; 28 (12): 2148-59. (Pubitemid 37468182)
153. Kunzel HE, Zobel AW, Nickel T, et al. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 2003 Nov-Dec; 37 (6): 525-33. (Pubitemid 37238946)
154. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the highaffinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000 May-Jun; 34 (3): 171-81. (Pubitemid 30364916)
155. Funk CK, Koob GF. A CRF(2) agonist administered into the central nucleus of the amygdala decreases ethanol selfadministration in ethanol-dependent rats. Brain Res 2007 Jun 25; 1155: 172-8. (Pubitemid 46900928)
156. Valdez GR, Sabino V, Koob GF. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 2004 Jun; 28 (6): 865-72. (Pubitemid 38780564)
157. Sharpe AL, Phillips TJ. Central urocortin 3 administration decreases limited-access ethanol intake in nondependent mice. Behav Pharmacol 2009 Jul; 20 (4): 346-51.
158. Wang B, You ZB, Rice KC, et al. Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRFbinding protein in the ventral tegmental area of the rat. Psychopharmacology (Berl) 2007 Aug; 193 (2): 283-94. (Pubitemid 47025028)
159. Vuong SM, Oliver HA, Scholl JL, et al. Increased anxietylike behavior of rats during amphetamine withdrawal is reversed by CRF2 receptor antagonism. Behav Brain Res 2010 Mar 17; 208 (1): 278-81.
160. Ruhmann A, Bonk I, Lin CR, et al. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 1998 Dec 22; 95 (26): 15264-9. (Pubitemid 29018687)
161. Bruijnzeel AW, Gold MS. The role of corticotropinreleasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Brain Res Rev 2005 Nov; 49 (3): 505-28. (Pubitemid 41546656)
162. Heilig M, Egli M, Crabbe JC, et al. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 2010 Apr; 15 (2): 169-84.
163. Bossert JM, Ghitza UE, Lu L, et al. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 2005 Dec 5; 526 (1-3): 36-50. (Pubitemid 41744104)
164. Rylkova D, Shah HP, Small E, et al. Deficit in brain reward function and acute and protracted anxiety-like behavior after discontinuation of a chronic alcohol liquid diet in rats. Psychopharmacology (Berl) 2009 Apr; 203 (3): 629-40.
165. Zhao Y, Weiss F, Zorrilla EP. Remission and resurgence of anxiety-like behavior across protracted withdrawal stages in ethanol-dependent rats. Alcohol Clin Exp Res 2007 Sep; 31 (9): 1505-15. (Pubitemid 47319664)
166. Valdez GR, Zorrilla EP, Roberts AJ, et al. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 2003 Feb; 29 (2): 55-60. (Pubitemid 36623341)
167. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci 2007 Nov; 8 (11): 844-58. (Pubitemid 350006216)
168. Fu Y, Pollandt S, Liu J, et al. Long-term potentiation (LTP) in the central amygdala (CeA) is enhanced after prolonged withdrawal from chronic cocaine and requires CRF1 receptors. J Neurophysiol 2007 Jan; 97 (1): 937-41. (Pubitemid 46143409)
169. Nie Z, Schweitzer P, Roberts AJ, et al. Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. Science 2004 Mar 5; 303 (5663): 1512-4. (Pubitemid 38314419)
170. Roberto M, Cruz MT, Gilpin NW, et al. Corticotropin releasing factor-induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence. Biol Psychiatry 2010 May 1; 67 (9): 831-9.
171. Pollandt S, Liu J, Orozco-Cabal L, et al. Cocaine withdrawal enhances long-term potentiation induced by corticotropin- releasing factor at central amygdala glutamatergic synapses via CRF,NMDAreceptors and PKA. Eur J Neurosci 2006 Sep; 24 (6): 1733-43. (Pubitemid 44427542)
172. Krishnan B, Centeno M, Pollandt S, et al. Dopamine receptor mechanisms mediate corticotropinreleasing factorinduced long-term potentiation in the rat amygdala following cocaine withdrawal. Eur J Neurosci 2010; 31: 1027-42.
173. Kash TL, Winder DG. Neuropeptide Y and corticotropinreleasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 2006 Oct; 51 (5): 1013-22. (Pubitemid 44528607)
174. Francesconi W, Berton F, Repunte-Canonigo V, et al. Protracted withdrawal from alcohol and drugs of abuse impairs long-term potentiation of intrinsic excitability in the juxtacapsular bed nucleus of the stria terminalis. J Neurosci 2009 Apr 29; 29 (17): 5389-401.
175. Hahn J, Hopf FW, Bonci A. Chronic cocaine enhances corticotropin- releasing factor-dependent potentiation of excitatory transmission in ventral tegmental area dopamine neurons. J Neurosci 2009 May 20; 29 (20): 6535-44